International Scholarly Research Notices / 2013 / Article / Tab 2

Research Article

Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy

Table 2

Immune phenotype over the course of the GRACE immunology substudy.

Median (range)BaselineWk 12Wk 48
AllaSuppressedbAllaSuppressedbAllaSuppressedb

CD4+ (%)15 (1, 33)15 (1, 33)16 (2, 36)17 (2, 36)21 (3, 40)21 (5, 40)
CD8+ (%)60.5 (39, 83)62 (42, 83)59 (35, 84)55 (36, 84)50 (27, 87)49 (27, 87)
CD4+/CD8+ ratio (%)0.22 (0.01, 0.70)0.22 (0.01, 0.70)0.30 (0.03, 1.00)0.36 (0.03, 1.00)0.41 (0.04, 1.21)0.52 (0.08, 1.21)
CD4+/CD38+/DR+ (%)22.5 (10, 88)22 (10, 88)19 (9, 76)18 (9, 53)13 (2, 36)11 (2, 36)
CD8+/CD38+/DR+ (%)48.5 (18, 76)47 (18, 76)36.5 (11, 71)34 (11, 62)25 (4, 68)22 (4, 52)
CD4+/CD95+ (%)15 (1, 35)16 (1, 35)21 (3, 38)22 (3, 38)23 (4, 41)24 (6, 41)
CD8+/CD95+ (%)71.5 (40, 87)70 (40, 87)69.5 (44, 88)66 (44, 88)55 (32, 80)49 (32, 79)
CD3+/CD4+/CD28+ (%)93 (46, 99)95 (56, 99)94 (67, 100)94 (70, 100)96 (67, 99)96 (67, 99)
CD3+/CD8+/CD28+ (%)59.5 (39, 86)62 (39, 85)50 (39, 79)50.5 (39, 79)56 (23, 82)56 (35, 82)

at baseline, at Wk 12 and at Wk 48; bHIV-RNA < 50 copies/mL at Wk 48 (or at Wks 36 and 52 if a Wk 48 sample was not available), .

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.